WINNIPEG, Sept. 5, 2012 /CNW/ - IMRIS Inc. (NASDAQ: IMRS); (TSX: IM)
("IMRIS" or the "Company") today is announcing that they have been
allowed the U.S. patent for MR Guided Radiation Therapy involving the
combination of radiation therapy and a moveable magnet system. In
addition, the U.S. Food & Drug Administration recently cleared the
first of several products in its MR Guided Radiation Therapy business.
The recently cleared MR imaging radiation oncology package is for
pelvic, brain, and head and neck imaging. The package includes MRI coil
sets and a specialized imaging tabletop intended for physicians
conducting diagnostic MR imaging for radiation therapy treatment
planning and simulation.
"We are on our way to building our image guided radiation therapy
business and producing essential tools for enhancing MR image targeting
in cancer treatments to support radiotherapy utilized by half of all
U.S. cancer patients each year," said David Graves, Chairman and CEO,
IMRIS. "This patent is significant. MR is the gold standard in soft
tissue imaging accuracy. Ultimately, we are working to improve
treatment targeting so patients in the future may have fewer radiation
sessions and experience less damage to healthy tissue adjacent to the
The oncology package is the first regulatory submission IMRIS filed with
the FDA for products related to image guided radiation therapy systems.
IMRIS (NASDAQ: IMRS; TSX: IM) is a global leader in providing image
guided therapy solutions through its VISIUS Surgical Theatre - a
revolutionary, multifunctional surgical environment that provides
unmatched intraoperative vision to clinicians to assist in decision
making and enhance precision in treatment. VISIUS Surgical Theatres
serve the neurosurgical, cardiovascular and cerebrovascular markets and
have been selected by leading medical institutions around the world.
SOURCE: IMRIS Inc.
For further information:
Director Investor Relations & Corporate Communications